Develops treatments for serious and orphan diseases of the central nervous system.
Cyclerion Therapeutics, Inc., headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing medicines for severe central nervous system (CNS) disorders. The company's primary focus lies in advancing innovative therapies that target significant unmet medical needs.
At the forefront of Cyclerion's pipeline is CY6463, a CNS-penetrant soluble guanylate cyclase (sGC) stimulator currently undergoing Phase IIa trials. This candidate shows promise in treating conditions such as mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology. Additionally, CY6463 is being evaluated in Phase 1 trials for schizophrenia in adults. Cyclerion is also developing Praliciguat, an oral systemic sGC stimulator in Phase II trials for resistant hypertension and diabetic nephropathy, and Olinciguat, an oral vascular sGC stimulator in Phase II trials for sickle cell disease. The company is actively pursuing CY3018 for CNS disorder treatments.
Cyclerion Therapeutics has established strategic partnerships, including a license agreement with Akebia Therapeutics, Inc., aimed at advancing the development, manufacturing, medical affairs, and commercialization of pharmaceutical products. This collaboration underscores Cyclerion's commitment to leveraging partnerships to accelerate the delivery of innovative therapies to patients in need. Founded in 2018, Cyclerion Therapeutics continues to expand its portfolio with a mission to address critical challenges in CNS diseases through cutting-edge scientific ressearch and development.